1.Inhibition of skeletal muscle proteolysis underlying the treatment of growth hormone combined with parenteral nutrition on surgical critical patients
Danian TONG ; Jim YANG ; Huanlong QIN
Chinese Journal of General Surgery 1993;0(01):-
Objective To study the effect of growth hormone (GH) combined with parenteral nutrition on skeletal muscle proteolysis for surgical critical patients. Methods Twenty surgical patients with APACHE II scores from 10 to 20 were divided randomly into two groups: parenteral nutrition group (PN group,n = 10) ; PN + GH ( GH group,n = 10). At the 5th day and 8th day during the study, urinary output of 3-methylhistidine ( 3-MH ) in 24 h urine were assessed with high performance liquid chromatography; at the 8th day the protein expressions of ubiquitin in quadriceps femoris muscle were determined by immunohistochemistry and the expressions of ubiquitin and C2 mRNA were determined by Northern blot analysis, the ultrastructure of quadriceps femoris muscle was observed under electronic microscope. All data were collected down in the form as mean ? standard deviation and analyzed with SPSS 11.5 for Windows. Results The urine level of 3-MH and the protein, mRNA and C2 mRNA expression of ubiquitin in quadriceps femoris muscle decreased in GH group as compared with PN group ( t = 4. 886, 6. 846,7. 314,5. 588,P
2.TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
Weidong ZHANG ; Hong YANG ; Zehua WANG ; Xiang JIM
Chinese Medical Journal 2002;115(12):1767-1771
OBJECTIVETo investigate the antitumor immune efficiency of mouse dendritic cells (mDCs) by using adenovirus-mediated tumor necrosis factor-alpha (AdV-TNF-alpha) gene transfer.
METHODSMDCs infected with AdV-TNF-alpha and AdV-pLpA (no gene insert) at 100 multiplicity of infection (MOI) were analyzed by RNase protection assay for their cytokine secretion. Mixed lymphocyte reactions were also performed to analyze their capacity for alloantigen-presentation. C57BL/6 mice were challenged with R3LL tumor cells (Lewis lung carcinoma line) 10 days after vaccination with different engineered DCs and regular DCs as well.
RESULTSCompared to AdV-pLpA and mock-infected DCs, AdV-TNF-alpha-infected DCs displayed up-regulated expression of alpha tumor necrosis factor, interleukin-12 (IL-12), interleukin-18 (IL-18) and granulocyte macrophage colony stimulation factor (GM-CSF), and indicated stronger allogeneic T cell proliferative responses. Furthermore, vaccination of mice with dendritic cell tumor necrosis factor-alpha (DCTNF-alpha) pulsed with Mut1 peptide induced more efficient tumor-specific cytotoxic T lymphocyte (CTL) cytotoxicity against R3LL tumor cells in vitro and with efficient antitumor immunity in vivo.
CONCLUSIONThis type of engineered DCs could be applied in clinical settings of DC-based cancer vaccines.
Adenoviridae ; genetics ; Animals ; Cytokines ; biosynthesis ; Cytotoxicity, Immunologic ; Dendritic Cells ; immunology ; Gene Transfer Techniques ; Genetic Therapy ; Lymphocyte Activation ; Mice ; Mice, Inbred C57BL ; Neoplasms, Experimental ; immunology ; therapy ; T-Lymphocytes, Cytotoxic ; immunology ; Tumor Necrosis Factor-alpha ; genetics
3.Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor.
Jung Sun CHO ; Sung Ho HER ; Ju Yeal BAEK ; Mahn Won PARK ; Hyoung Doo KIM ; Myung Ho JEONG ; Young keun AHN ; Shung Chull CHAE ; Seung Ho HUR ; Taek Jong HONG ; Young Jo KIM ; In Whan SEONG ; Jei Keon CHAE ; Jay Young RHEW ; In Ho CHAE ; Myeong Chan CHO ; Jang Ho BAE ; Seung Woon RHA ; Chong Jim KIM ; Donghoon CHOI ; Yang Soo JANG ; Junghan YOON ; Wook Sung CHUNG ; Jeong Gwan CHO ; Ki Bae SEUNG ; Seung Jung PARK
Journal of Korean Medical Science 2010;25(11):1601-1608
The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.
Acute Disease
;
Aged
;
Drug Therapy, Combination
;
Female
;
Hemorrhage
;
Heparin/*therapeutic use
;
Heparin, Low-Molecular-Weight/*therapeutic use
;
Humans
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Myocardial Infarction/epidemiology/mortality/*therapy
;
Myocardial Revascularization
;
Odds Ratio
;
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors/metabolism
;
Prognosis
;
Registries
4.Comparison of Clinical Outcomes Following Acute Myocardial Infarctions in Hypertensive Patients With or Without Diabetes.
Min Goo LEE ; Myung Ho JEONG ; Youngkeun AHN ; Shung Chull CHAE ; Seung Ho HUR ; Taek Jong HONG ; Young Jo KIM ; In Whan SEONG ; Jei Keon CHAE ; Jay Young RHEW ; In Ho CHAE ; Myeong Chan CHO ; Jang Ho BAE ; Seung Woon RHA ; Chong Jim KIM ; Donghoon CHOI ; Yang Soo JANG ; Junghan YOON ; Wook Sung CHUNG ; Jeong Gwan CHO ; Ki Bae SEUNG ; Seung Jung PARK
Korean Circulation Journal 2009;39(6):243-250
BACKGROUND AND OBJECTIVES: It is thought that patients with diabetes mellitus (DM) have a poor prognosis after an acute myocardial infarction (AMI), but the effect of diabetes on the outcomes of hypertensive patients with AMIs has not been elucidated in the Korean population. The aim of this study was to investigate the effects of diabetes on long-term clinical outcomes following AMIs in patients with hypertension. SUBJECTS AND METHODS: Using data from the Korea Acute Myocardial Infarction Registry (November 2005 to December 2006), 2,233 hypertensive patients with AMIs were grouped as follows based on the presence of DM: group I, diabetic hypertension (n=892, 544 men, mean age=66.2+/-10.9 years); and group II, non-diabetic hypertension (n=1341, 938 men, mean age=63.9+/-12.8 years). The primary study outcomes included in-hospital death and major adverse cardiac events (MACE; cardiac death, myocardial infarction (MI), repeat percutaneous coronary intervention, and coronary artery bypass surgery) at the 1 year follow-up. RESULTS: Hypertensive patients with DM were older and more likely to be women. The diabetic group had lower blood pressure (p<0.001), a lower left ventricular ejection fraction (p<0.001), a more severe degree of heart failure (p<0.001), a longer duration of coronary care unit admission (p<0.001), and a higher incidence of hyperlipidemia (p=0.007). The N-terminal pro-brain natriuretic peptide level (4602.5+/-8710.6 pg/mL vs. 2320.8+/-5837.9 pg/mL, p<0.001) was higher and the creatinine clearance (62.4+/-29.9 mL/min vs. 73.0+/-40.8 mL/min, p<0.001) was lower in the diabetic group than the non-diabetic group. Coronary angiographic findings revealed more frequent involvement of the left main stem (p=0.002) and multiple vessels (p<0.001) in the diabetic group. The rate of in-hospital death was higher in the diabetic group (p<0.001). During follow-up, the rates of composite MACE at 1 month, 6 months, and 12 months were higher in the diabetic group (p<0.001). CONCLUSION: In hypertensive patients with AMI, DM was associated with worse clinical and angiographic features, with a higher risk of development of severe heart failure, and an increased risk of MACE on long-term clinical follow-up.
Blood Pressure
;
Coronary Artery Bypass
;
Coronary Care Units
;
Creatinine
;
Death
;
Diabetes Mellitus
;
Female
;
Follow-Up Studies
;
Heart Failure
;
Humans
;
Hyperlipidemias
;
Hypertension
;
Incidence
;
Korea
;
Male
;
Myocardial Infarction
;
Percutaneous Coronary Intervention
;
Prognosis
;
Stroke Volume
5. Treatment advice of small molecule antiviral drugs for elderly COVID-19
Min PAN ; Shuang CHANG ; Xiao-Xia FENG ; Guang-He FEI ; Jia-Bin LI ; Hua WANG ; Du-Juan XU ; Chang-Hui WANG ; Yan SUN ; Xiao-Yun FAN ; Tian-Jing ZHANG ; Wei WEI ; Ling-Ling ZHANG ; Jim LI ; Fei-Hu CHEN ; Xiao-Ming MENG ; Hong-Mei ZHAO ; Min DAI ; Yi XIANG ; Meng-Shu CAO ; Xiao-Yang CHEN ; Xian-Wei YE ; Xiao-Wen HU ; Ling JIANG ; Yong-Zhong WANG ; Hao LIU ; Hai-Tang XIE ; Ping FANG ; Zhen-Dong QIAN ; Chao TANG ; Gang YANG ; Xiao-Bao TENG ; Chao-Xia QIAN ; Guo-Zheng DING
Chinese Pharmacological Bulletin 2023;39(3):425-430
COVID-19 has been prevalent for three years. The virulence of SARS-CoV-2 is weaken as it mutates continuously. However, elderly patients, especially those with underlying diseases, are still at high risk of developing severe infections. With the continuous study of the molecular structure and pathogenic mechanism of SARS-CoV-2, antiviral drugs for COVID-19 have been successively marketed, and these anti-SARS-CoV-2 drugs can effectively reduce the severe rate and mortality of elderly patients. This article reviews the mechanism, clinical medication regimens, drug interactions and adverse reactions of five small molecule antiviral drugs currently approved for marketing in China, so as to provide advice for the clinical rational use of anti-SARS-CoV-2 in the elderly.